{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:59:44Z","timestamp":1761897584678},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is a controversy over the association between obesity and the risk of renal events in patients with type 2 diabetes mellitus (T2DM). Furthermore, whether body weight (BW) loss following sodium glucose cotransporter 2 inhibitor (SGLT2i) treatment associated with risk of adverse renal events is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used medical data from a multi-center healthcare provider in Taiwan, enrolling 8992 T2DM patients with a baseline\/following-up BW data available after around 12\u00a0weeks of SGLT2i treatment, from June 1, 2016 to December 31, 2018. Patients were followed up until the occurrence of composite renal outcome (estimated glomerular filtration rate decline\u2009&gt;\u200940% or end-stage kidney disease) or the end of study period, whichever occurred first.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants were divided into six baseline BMI categories:\u2009&lt;\u200918.5 (n\u2009=\u200955); 18.5\u201322.9 (n\u2009=\u2009985); 23.0\u201324.9 (n\u2009=\u20091389); 25.0\u201329.9 (n\u2009=\u20093941); 30.0\u201334.9 (n\u2009=\u20091973); and \u2265 35.0\u00a0kg\/m<jats:sup>2<\/jats:sup> (n\u2009=\u2009649). There were 38.9%, 23.5%, 24.7%, 8.4%, 2.7%, and 1.8% of patients experienced no-BW loss, initial BW loss of 0.0\u20132.4%, 2.5\u20134.9%, 5.0\u20137.4%, 7.5\u20139.9%, and \u2265 10.0%, associated with SGLT2i treatment, respectively. Compared with patients with normal BMI (BMI: 18.5\u201322.9\u00a0kg\/m<jats:sup>2<\/jats:sup>), underweight (BMI: &lt;\u200918.5\u00a0kg\/m<jats:sup>2<\/jats:sup>) was associated with a higher risk of composite renal outcome (adjusted hazard ratio (aHR) [95% confidence intervals (CI)]: 2.17; [1.16\u20134.04]), whereas pre-obese (BMI: 25.0\u201329.9\u00a0kg\/m<jats:sup>2<\/jats:sup>) associated with the lowest risk of composite renal outcome (0.52; [0.40\u20130.68]) after multivariate adjustment. Compared with those without BW loss after SGLT2i treatment, BW loss of 0.0\u20132.4% (0.55; [0.43\u20130.70]) and 2.5\u20134.9% (0.78; [0.63\u20130.98]) were associated with a lower risk, whereas BW loss \u2265 10.0% associated with a higher risk of composite renal outcome (1.61; [1.06\u20132.46]) after multivariate adjustment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A modest BW loss of 0\u20135% associated with SGLT2i treatment was associated with a favorable renal outcome. Caution should be taken for whom are underweight at baseline or have a pronounced BW loss \u2265 10.0% associated with SGLT2i treatment, which was associated with a worse renal outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01361-z","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T12:03:51Z","timestamp":1629115431000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors"],"prefix":"10.1186","volume":"20","author":[{"given":"Yi-Hsin","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wei","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pao-Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"1 Suppl","key":"1361_CR1","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2013.11.001","volume":"63","author":"AJ Collins","year":"2014","unstructured":"Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske BL, Kutner N, Liu J, et al. US renal data system 2013 annual data report. Am J Kidney Dis. 2014;63(1 Suppl):A7.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1361_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.2337\/dc20-0352","volume":"43","author":"JI Morton","year":"2020","unstructured":"Morton JI, Liew D, McDonald SP, Shaw JE, Magliano DJ. The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease: a national registry study. Diabetes Care. 2020;43(8):1788\u201395.","journal-title":"Diabetes Care"},{"issue":"3","key":"1361_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.ajkd.2018.10.005","volume":"73","author":"DN Koye","year":"2019","unstructured":"Koye DN, Magliano DJ, Reid CM, Pavkov ME, Chadban SJ, McDonald SP, Polkinghorne KR, White S, Paul C, Shaw JE. Trends in incidence of ESKD in people with type 1 and type 2 diabetes in Australia, 2002\u20132013. Am J Kidney Dis. 2019;73(3):300\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1361_CR4","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1093\/ndt\/gfh540","volume":"19","author":"CE Lok","year":"2004","unstructured":"Lok CE, Oliver MJ, Rothwell DM, Hux JE. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant. 2004;19(12):3098\u2013103.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-013-2966-1","volume":"56","author":"MA Schroijen","year":"2013","unstructured":"Schroijen MA, van de Luijtgaarden MW, Noordzij M, Ravani P, Jarraya F, Collart F, Prutz KG, Fogarty DG, Leivestad T, Prischl FC, et al. Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. Diabetologia. 2013;56(9):1949\u201357.","journal-title":"Diabetologia"},{"issue":"15","key":"1361_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1361_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1361_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"1361_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1361_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"10","key":"1361_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"1","key":"1361_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19\u201333.","journal-title":"Kidney Int"},{"issue":"7","key":"1361_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.291.7.844","volume":"291","author":"CS Fox","year":"2004","unstructured":"Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844\u201350.","journal-title":"JAMA"},{"issue":"1","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41387-017-0012-y","volume":"8","author":"K Mohammedi","year":"2018","unstructured":"Mohammedi K, Chalmers J, Herrington W, Li Q, Mancia G, Marre M, Poulter N, Rodgers A, Williams B, Perkovic V, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018;8(1):7.","journal-title":"Nutr Diabetes"},{"issue":"5","key":"1361_CR16","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1523-1755.2004.00582.x","volume":"65","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65(5):1870\u20136.","journal-title":"Kidney Int"},{"issue":"1","key":"1361_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"CY Hsu","year":"2006","unstructured":"Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21\u20138.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1361_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/1753-0407.12514","volume":"9","author":"HF Chung","year":"2017","unstructured":"Chung HF, Al Mamun A, Huang MC, Long KZ, Huang YF, Shin SJ, Hwang SJ, Hsu CC. Obesity, weight change, and chronic kidney disease in patients with type 2 diabetes mellitus: a longitudinal study in Taiwan. J Diabetes. 2017;9(11):983\u201393.","journal-title":"J Diabetes"},{"issue":"5","key":"1361_CR19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2337\/dc19-2095","volume":"43","author":"YH Kim","year":"2020","unstructured":"Kim YH, Kang JG, Lee SJ, Han KD, Ihm SH, Cho KH, Park YG. Underweight increases the risk of end-stage renal diseases for type 2 diabetes in Korean population: data from the National Health Insurance Service Health Checkups 2009\u20132017. Diabetes Care. 2020;43(5):1118\u201325.","journal-title":"Diabetes Care"},{"issue":"12","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2337\/dc08-0971","volume":"31","author":"AO Luk","year":"2008","unstructured":"Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, Yu LW, Lau WW, Yang X, Chow FC, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008;31(12):2357\u201361.","journal-title":"Diabetes Care"},{"issue":"5","key":"1361_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chan YY, Kao Yang YH, Lin SJ, Hung MJ, Chien RN, Lai CC, Lai EC. The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28(5):593\u2013600.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0970-0218.173492","volume":"41","author":"S Girdhar","year":"2016","unstructured":"Girdhar S, Sharma S, Chaudhary A, Bansal P, Satija M. An epidemiological study of overweight and obesity among women in an urban area of North India. Indian J Community Med. 2016;41(2):154\u20137.","journal-title":"Indian J Community Med"},{"issue":"10","key":"1361_CR23","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1681\/ASN.2007020199","volume":"18","author":"LA Stevens","year":"2007","unstructured":"Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1361_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1361_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342\u201350.","journal-title":"Arch Intern Med"},{"issue":"10","key":"1361_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","volume":"2","author":"ARG Look","year":"2014","unstructured":"Look ARG. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1361_CR27","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1681\/ASN.2007121286","volume":"19","author":"S Ryu","year":"2008","unstructured":"Ryu S, Chang Y, Woo HY, Kim SG, Kim DI, Kim WS, Suh BS, Choi NK, Lee JT. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol. 2008;19(9):1798\u2013805.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1361_CR28","doi-asserted-by":"publisher","first-page":"e0143434","DOI":"10.1371\/journal.pone.0143434","volume":"10","author":"E Kanda","year":"2015","unstructured":"Kanda E, Muneyuki T, Suwa K, Nakajima K. Effects of weight loss speed on kidney function differ depending on body mass index in nondiabetic healthy people: a prospective cohort. PLoS ONE. 2015;10(11):e0143434.","journal-title":"PLoS ONE"},{"issue":"9","key":"1361_CR29","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","volume":"115","author":"MJ Franz","year":"2015","unstructured":"Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115(9):1447\u201363.","journal-title":"J Acad Nutr Diet"},{"issue":"17","key":"1361_CR30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","volume":"366","author":"PR Schauer","year":"2012","unstructured":"Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567\u201376.","journal-title":"N Engl J Med"},{"issue":"3","key":"1361_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330.","journal-title":"Drugs"},{"issue":"4","key":"1361_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13300-016-0193-8","volume":"7","author":"J Wilding","year":"2016","unstructured":"Wilding J, Bailey C, Rigney U, Blak B, Beekman W, Emmas C. Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther. 2016;7(4):695\u2013711.","journal-title":"Diabetes Ther"},{"issue":"2","key":"1361_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.12578","volume":"18","author":"SP Rajeev","year":"2016","unstructured":"Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18(2):125\u201334.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1361_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","volume":"20","author":"E Brown","year":"2019","unstructured":"Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816\u201328.","journal-title":"Obes Rev"},{"issue":"2","key":"1361_CR35","doi-asserted-by":"publisher","first-page":"e14360","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):e14360.","journal-title":"Physiol Rep"},{"issue":"1","key":"1361_CR36","doi-asserted-by":"publisher","first-page":"e000742","DOI":"10.1136\/bmjdrc-2019-000742","volume":"7","author":"SC Shao","year":"2019","unstructured":"Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care. 2019;7(1):e000742.","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01361-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01361-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01361-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T12:05:49Z","timestamp":1629115549000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01361-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01361-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"26 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complies with the Declaration of Helsinki and was approved by the Institutional Review Board of the Chang Gung Medical Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used in this study were only available in the Chang Gung Medical Data Center, Taiwan. The programs (codes) involved for this study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}